Literature DB >> 8754855

Precise alignment of sites required for mu enhancer activation in B cells.

B S Nikolajczyk1, B Nelsen, R Sen.   

Abstract

The lymphocyte-specific immunoglobulin mu heavy-chain gene intronic enhancer is regulated by multiple nuclear factors. The previously defined minimal enhancer containing the muA, muE3, and muB sites is transactivated by a combination of the ETS-domain proteins PU.1 and Ets-1 in nonlymphoid cells. The core GGAAs of the muA and muB sites are separated by 30 nucleotides, suggesting that ETS proteins bind to these sites from these same side of the DNA helix. We tested the necessity for appropriate spatial alignment of these elements by using mutated enhancers with altered spacings. A 4- or 10-bp insertion between muE3 and muB inactivated the mu enhancer in S194 plasma cells but did not affect in vitro binding of Ets-1, PU.1, or the muE3-binding protein TFE3, alone or in pairwise combinations. Circular permutation and phasing analyses demonstrated that PU.1 binding but not TFE3 or Ets-1 bends mu enhancer DNA toward the major groove. We propose that the requirement for precise spacing of the muA and muB elements is due in part to a directed DNA bend induced by PU.1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8754855      PMCID: PMC231453          DOI: 10.1128/MCB.16.8.4544

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  61 in total

1.  The HMG domain of lymphoid enhancer factor 1 bends DNA and facilitates assembly of functional nucleoprotein structures.

Authors:  K Giese; J Cox; R Grosschedl
Journal:  Cell       Date:  1992-04-03       Impact factor: 41.582

Review 2.  Regulation of immunoglobulin gene transcription.

Authors:  B Nelsen; R Sen
Journal:  Int Rev Cytol       Date:  1992

3.  A novel modulator domain of Ets transcription factors.

Authors:  C Wasylyk; J P Kerckaert; B Wasylyk
Journal:  Genes Dev       Date:  1992-06       Impact factor: 11.361

4.  Stereospecific alignment of the X and Y elements is required for major histocompatibility complex class II DRA promoter function.

Authors:  B J Vilen; J P Cogswell; J P Ting
Journal:  Mol Cell Biol       Date:  1991-05       Impact factor: 4.272

5.  Fos-Jun heterodimers and Jun homodimers bend DNA in opposite orientations: implications for transcription factor cooperativity.

Authors:  T K Kerppola; T Curran
Journal:  Cell       Date:  1991-07-26       Impact factor: 41.582

6.  DNA bending by Fos and Jun: the flexible hinge model.

Authors:  T K Kerppola; T Curran
Journal:  Science       Date:  1991-11-22       Impact factor: 47.728

7.  A dominant negative form of transcription activator mTFE3 created by differential splicing.

Authors:  C Roman; L Cohn; K Calame
Journal:  Science       Date:  1991-10-04       Impact factor: 47.728

8.  The solution structure of the human ETS1-DNA complex reveals a novel mode of binding and true side chain intercalation.

Authors:  M H Werner; M Clore; C L Fisher; R J Fisher; L Trinh; J Shiloach; A M Gronenborn
Journal:  Cell       Date:  1995-12-01       Impact factor: 41.582

9.  mTFE3, an X-linked transcriptional activator containing basic helix-loop-helix and zipper domains, utilizes the zipper to stabilize both DNA binding and multimerization.

Authors:  C Roman; A G Matera; C Cooper; S Artandi; S Blain; D C Ward; K Calame
Journal:  Mol Cell Biol       Date:  1992-02       Impact factor: 4.272

10.  DNA binding by c-Ets-1, but not v-Ets, is repressed by an intramolecular mechanism.

Authors:  F Lim; N Kraut; J Framptom; T Graf
Journal:  EMBO J       Date:  1992-02       Impact factor: 11.598

View more
  14 in total

1.  Mutants of ETS domain PU.1 and GGAA/T recognition: free energies and kinetics.

Authors:  F Pio; N Assa-Munt; J Yguerabide; R A Maki
Journal:  Protein Sci       Date:  1999-10       Impact factor: 6.725

2.  Transcriptional activation by ETS and leucine zipper-containing basic helix-loop-helix proteins.

Authors:  G Tian; B Erman; H Ishii; S S Gangopadhyay; R Sen
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

3.  Precise arrangement of factor-binding sites is required for murine CD4 promoter function.

Authors:  S Sarafova; G Siu
Journal:  Nucleic Acids Res       Date:  2000-07-15       Impact factor: 16.971

4.  Activation of c-myc promoter P1 by immunoglobulin kappa gene enhancers in Burkitt lymphoma: functional characterization of the intron enhancer motifs kappaB, E box 1 and E box 2, and of the 3' enhancer motif PU.

Authors:  N E Wittekindt; K Hörtnagel; C Geltinger; A Polack
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

5.  Evolution of transcriptional enhancers in the immunoglobulin heavy-chain gene: functional characteristics of the zebrafish Emu3' enhancer.

Authors:  Kristofor K Ellestad; Brad G Magor
Journal:  Immunogenetics       Date:  2005-03-09       Impact factor: 2.846

6.  Biased dA/dT somatic hypermutation as regulated by the heavy chain intronic iEmu enhancer and 3'Ealpha enhancers in human lymphoblastoid B cells.

Authors:  Atsumasa Komori; Zhenming Xu; Xiaoping Wu; Hong Zan; Paolo Casali
Journal:  Mol Immunol       Date:  2006-01-10       Impact factor: 4.407

7.  Exploring functional redundancy in the immunoglobulin mu heavy-chain gene enhancer.

Authors:  W Dang; B S Nikolajczyk; R Sen
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

8.  ETS-mediated cooperation between basic helix-loop-helix motifs of the immunoglobulin mu heavy-chain gene enhancer.

Authors:  W Dang; X H Sun; R Sen
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

9.  Combinatorial determinants of tissue-specific transcription in B cells and macrophages.

Authors:  B S Nikolajczyk; M Cortes; R Feinman; R Sen
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

10.  Conservation and divergence of the Emicro3' enhancer in the IGH locus of teleosts.

Authors:  Jun-Ichi Hikima; Mara L Lennard; Melanie R Wilson; Norman W Miller; L William Clem; Gregory W Warr
Journal:  Immunogenetics       Date:  2006-03-15       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.